Corporate Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
Life-cycle development Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs
Life-cycle development Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets
Partnership Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV in The Oncologist
Life-cycle development Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia
News Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region
Partnership Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy
News Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting
